NCT05216224Phase 2Completed

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Study sponsor: Aclaris Therapeutics, Inc. · ACRS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-12-23Actual

Enrollment · participants95Actual

Source updated2026-01-07Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-01-07 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Efficacy measured as the change from Baseline in inflammatory nodule/abscess count at Week 12.

+ Updated value

measure: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Study details

Conditions studied

Hidradenitis Suppurativa

Treatments or interventions studied

ATI-450DrugAlso known as Zunsemetinib
Placebo oral tabletDrugAlso known as Placebo

Primary outcomes · main study measures

measure: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12; description: AN count was the sum of number of abscess and inflammatory nodules across anatomical regions. The least square (LS) mean change from baseline in the count at Week 12 was estimated from the Mixed Model Repeated Measures (MMRM) model.; timeFrame: Baseline, Week 12

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history